common.study.topics.clinical

Pharmacogenomics and Post-Operative Nausea and Vomiting

common.study.values.description

“Pharmacogenomics and Post-Operative Nausea and Vomiting”

The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - Granisetron

Rapid metabolizer will receive 1mg IV Granisetron

Drug - Ondansetron

Poor or normal metabolizers will receive 4mg Ondansetron IV

participant.views.study.view.additional

participant.views.study.view.scientific-title

Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study

common.study.values.clinical-trial-id

NCT03503292

participant.views.study.view.id

BeX1Va